Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Core	STARTED	Imatinib Mesylate 400 mg	74
Core	STARTED	Imatinib Mesylate 600 mg	74
Core	Treated Participants	Imatinib Mesylate 400 mg	73
Core	Treated Participants	Imatinib Mesylate 600 mg	74
Core	COMPLETED	Imatinib Mesylate 400 mg	30
Core	COMPLETED	Imatinib Mesylate 600 mg	37
Core	NOT COMPLETED	Imatinib Mesylate 400 mg	44
Core	NOT COMPLETED	Imatinib Mesylate 600 mg	37
Extension	STARTED	Imatinib Mesylate 400 mg	24
Extension	STARTED	Imatinib Mesylate 600 mg	32
Extension	COMPLETED	Imatinib Mesylate 400 mg	8
Extension	COMPLETED	Imatinib Mesylate 600 mg	13
Extension	NOT COMPLETED	Imatinib Mesylate 400 mg	16
Extension	NOT COMPLETED	Imatinib Mesylate 600 mg	19

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00237185/flow